Literature DB >> 2347368

Type II collagen-specific human T cell lines established from healthy donors.

M Lacour1, U Rudolphi, M Schlesier, H H Peter.   

Abstract

Four type II collagen-specific T cell lines established from the peripheral blood of a healthy donor were studied in detail. These CD4+ T cell lines with an alpha/beta T cell receptor proliferated in response to native and denatured human and chicken type II collagen and human type I collagen, but not to human type IV collagen or other potentially arthritogenic antigens. The T cell response showed typical dose response characteristics, peaked between 30 and 48 h, was major histocompatibility complex class II restricted and not due to a mitogenic effect. Type II collagen-reactive T cells could hardly be detected in freshly isolated peripheral blood mononuclear cells from healthy donors, as revealed by limiting dilution analysis (frequency less than 1/100,000). By prestimulation in bulk cultures for 10 days, type II collagen-reactive T cells could be approximately 1000-fold enriched. However, in these limiting dilution cultures, collagen-reactive T cells could only be observed in a narrow window of cell concentrations, suggesting that type II collagen-reactive T cells may be controlled by suppressive mechanisms in healthy persons.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2347368     DOI: 10.1002/eji.1830200432

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  2 in total

Review 1.  A walk round the edges of self tolerance.

Authors:  N A Mitchison
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

2.  Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis.

Authors:  Johan Bäcklund; Stefan Carlsen; Torsten Höger; Björn Holm; Lars Fugger; Jan Kihlberg; Harald Burkhardt; Rikard Holmdahl
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-27       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.